TY - JOUR
T1 - Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels
AU - Santini, Valeria
AU - Almeida, Antonio
AU - Giagounidis, Aristoteles
AU - Skikne, Barry
AU - Beach, C. L.
AU - Weaver, Jerry
AU - Tu, Nora
AU - Fenaux, Pierre
PY - 2020/5/11
Y1 - 2020/5/11
N2 - In the randomized, phase 3, MDS-005 study (NCT01029262), lenalidomide-induced red blood cell transfusion independence (RBC-TI) in 27% of transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes (MDS) ineligible for or refractory to erythropoiesis-stimulating agents. To determine the influence of erythropoietin (EPO) level on response, 155 patients treated with lenalidomide in MDS-005 were categorized into four groups by baseline EPO level. The EPO >500 mU/mL group had higher RBC transfusion burden and the lowest proportion of patients with ring sideroblasts ≥15% versus lower EPO groups. Achievement of RBC-TI ≥8 weeks inversely correlated with EPO level, ranging from 42.5 to 15.5%. EPO level did not affect erythroid hematologic improvement response (36.2–44.4%). This analysis suggests patients with lower EPO levels experience the strongest benefit from lenalidomide. Although meaningful improvements were observed in some patients with EPO level >500 mU/mL, new treatments are needed for this population.
AB - In the randomized, phase 3, MDS-005 study (NCT01029262), lenalidomide-induced red blood cell transfusion independence (RBC-TI) in 27% of transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes (MDS) ineligible for or refractory to erythropoiesis-stimulating agents. To determine the influence of erythropoietin (EPO) level on response, 155 patients treated with lenalidomide in MDS-005 were categorized into four groups by baseline EPO level. The EPO >500 mU/mL group had higher RBC transfusion burden and the lowest proportion of patients with ring sideroblasts ≥15% versus lower EPO groups. Achievement of RBC-TI ≥8 weeks inversely correlated with EPO level, ranging from 42.5 to 15.5%. EPO level did not affect erythroid hematologic improvement response (36.2–44.4%). This analysis suggests patients with lower EPO levels experience the strongest benefit from lenalidomide. Although meaningful improvements were observed in some patients with EPO level >500 mU/mL, new treatments are needed for this population.
KW - Erythropoietin
KW - Lenalidomide
KW - Myelodysplastic syndromes
UR - http://www.scopus.com/inward/record.url?scp=85079724333&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1719088
DO - 10.1080/10428194.2020.1719088
M3 - Article
C2 - 32064987
AN - SCOPUS:85079724333
SN - 1042-8194
VL - 61
SP - 1475
EP - 1483
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -